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Abstract
α-synuclein is a small soluble, cytosolic protein which associates with vesicular membranes. It is a
component of intracellular Lewy bodies present in Parkinson's disease and a subset of Alzheimer's
disease (AD). In addition, early studies identified a fragment of α-synuclein in the amyloid plaques
of AD patients. Hypothesizing that α-synuclein might modify the AD pathogenic process, we
crossed the Tg2576 strain of APP transgenic mice onto an α-synuclein knockout background to
determine the effects of α-synuclein on Aβ production and plaque deposition. We found that α-
synuclein deficiency does not affect the Aβ levels, nor does it alter the age of onset of plaque
pathology. To our surprise, however, loss of α-synuclein leads to a significant increase in plaque
load in all areas of the forebrain at 18 months of age. This is associated with an increase in another
synaptic protein, synaptophysin. We thus conclude that α-synuclein is not involved in seeding of
the plaques, but rather suppresses the progression of plaque pathology at advanced stages.
Background
Alzheimer's disease (AD) and Parkinson's disease (PD)
are the two most common age-dependent disorders of the
central nervous system [1] conferring a detrimental neuro-
degenerative phenotype on the individual. In both dis-
eases a subset of cases has been linked to autosomal
dominant mutations in specific genes. While in inherited
cases of AD, genetic mutations in amyloid precursor pro-
tein (APP) and presenilins (PS1 and PS2) lead to the path-
ological features of extracellular Aβ plaques and
intracellular neurofibrillary tangles [2], mutations in the
α-synuclein gene (Snca) confer familial PD, and its pro-
tein product is a component of the pathological hallmark,
the intracellular Lewy bodies [3,4]. More than a decade
ago evidence emerged that the Aβ plaques contain a pep-
tide then termed "non-amyloid component of Aβ
plaques" (NAC) [5,6], which was later identified as a frag-
ment of α-synuclein. The 35 amino acid fragment found
in the plaques was determined to be extremely hydropho-
bic [7], and multiple lines of evidence indicated that α-
synuclein aids the aggregation of Aβ42 in vitro and might
be involved in the formation of Aβ plaques in the brains
of patients with AD and dementia with Lewy bodies
(DLB) [8]. Studies by Yang et al. [9] suggested that α-synu-
clein was the major component accumulating in the neu-
rites of aged Tg2576 APP transgenic mice and suggested
that this aggregation might be caused by Aβ peptides.
Other studies have generated in vivo data using overex-
pression of APP, leading to an increase of hydrophobic
accumulations in a mouse model also overexpressing α-
synuclein [10]. Together these published data indicate
that α-synuclein might interact with other fibrillogenic
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proteins and enhance their accumulation and in return is
positively influenced to aggregate as well. However, this
detrimental function of α-synuclein has also been called
into question as a few publications failed to establish any
association between α-synuclein and Aβ pathology [11].
Although multiple α-synuclein transgenic lines have been
created, which mimic some aspects of PD pathology [12],
no studies have been reported on how the lack of α-synu-
clein affects the progression of neurodegenerative dis-
eases. Several lines of α-synuclein (Snca) knockout mice
have been established, most of which show only a very
mild phenotype, suggesting genetic redundancy [13-15].
These studies suggested that α-synuclein is not an essen-
tial component of the neuronal system under normal cir-
cumstances or that other proteins may compensate for the
loss of α-synuclein [16].
Based on published reports, we hypothesized that α-synu-
clein in an AD mouse model overexpressing APP would
likely support the aggregation of Aβ plaques and its
absence would result in a decreased number of plaques
and a belated onset of pathology. We thus bred the Snca
knockout mice [14] with Tg2576 [17] mice overexpress-
ing mutant human APP that develop amyloid plaque
pathology at 9–10 months of age, and the number of
plaques increased dramatically with age [17].
Results
In our study we used aged Tg2576 animals, herein referred
to as APP animals, and compared their plaque pathology
to that of APP animals lacking α-synuclein (APP/Snca-/-)
at various ages. In general the mice are indistinguishable
from their littermates in terms of appearance and viabil-
ity. In order to determine whether we could detect differ-
ences in the production of two main Aβ species we
performed Sandwich ELISA experiments at an early age. At
6 months of age neither the APP nor the APP/Snca-/-
exhibit Aβ plaque pathology (data not shown). As
expected, no difference in Aβ40 or Aβ42 levels could be
detected by Sandwich ELISA (Figure 1) when comparing
6-month-old APP and APP/Snca-/-  animals. We then
focused our study to determine the effects of α-synuclein
on the onset of plaque deposition, and the progression of
the pathology by comparing these parameters between
APP and APP/Snca-/-.
In order to determine whether the age of onset of plaque
deposition is affected, we studied 9-month-old APP and
APP/Snca-/-  animals as that is the earliest time when
plaques can be detected in APP mice. Using immunohis-
tochemistry with 6E10 antibody to human APP, we
detected a slight increase in the number of plaques (Figure
2A), but the difference failed to reach statistical signifi-
cance (Figure 2B). The number of plaques increased in
both APP and APP/Snca-/- mice at 12 months (Figure 2).
Similar to 9-month-old animals, there was a slight, but
not statistically significant, difference between the two
genotypes in the number or size of plaques (Figure 2B). As
a homologous protein to α-synuclein, we studied the pro-
tein levels of β-synuclein as well as another synaptic vesi-
cle protein, synaptophysin, in the brain homogenates of
APP and APP/Snca-/- mice. We were unable to detect sig-
nificant differences in the expression of β-synuclein or
synaptophysin in brain homogenates, limiting the possi-
bility that these presynaptic proteins play a compensatory
role for the loss of α-synuclein (Figure 2C). Overall, it
appears that α-synuclein is not a large player in initiation/
seeding of the plaque pathology in APP mice.
At 18 months of age, however, differences in the number
of plaques became obvious. When performing 6E10 and
thioflavine S staining of comparable coronal sections, we
observed a vastly increased number of plaques in the APP/
Snca-/- animals when compared to APP animals (Figure
3A). Because the number of plaques in APP/Snca-/- mice
reached a level that was difficult to be counted manually,
we chose to quantify the plaque density by assessing the
signal intensity of matched areas. Statistical analysis
revealed that both total (6E10-positive) and dense-core
plaque (thioflavin S-positive) load in the APP/Snca-/- ani-
mals were increased 3–4 fold when compared to the
number of plaques found in age-matched Tg2576 animals
(p < 0.001).
As expected, Western blot analysis showed that α-synu-
clein protein was missing from the brain homogenates of
the APP/Snca-/- animals (Figure 4A) and the levels of full-
length APP were not affected by the absence of α-synu-
clein. Once again we were unable to detect an increase in
the β-synuclein (Figure 4A). Unexpectedly, we found that
synaptophysin, which was unchanged at 12 months, was
up-regulated by two-fold in APP/Snca-/- animals when
compared to APP animals (Figure 4B, p < 0.01). This
could be attributed to a compensatory mechanism acti-
vated due to α-synuclein deficiency. However, the reason
for the selective increase of synaptophysin, but not β-
synuclein, is not clear.
Discussion
Genetic mutations and gene amplification of α-synuclein
(Snca) are linked to familial Parkinson's disease, and
aggregation of the protein is the pathological hallmark of
the disease. Numerous studies have focused on the effect
that the overexpression of α-synuclein has on the
dopaminergic system. In this pathogenic state, even as lit-
tle as a two-fold increase in protein expression leads to the
pathological feature of PD [12]. However, its normal
function is much less understood. Early studies of knock-
out animals lacking either α- or β-synuclein or bothMolecular Neurodegeneration 2007, 2:6 http://www.molecularneurodegeneration.com/content/2/1/6
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revealed little impact on the mammalian system. Mice
lacking the protein are phenotypically normal, and only
close investigation reveals slight deficits such as a reduc-
tion in dopamine levels [12,13].
It is well established that α-synuclein localizes to the pre-
synaptic terminals and associates with synaptic vesicles. In
addition the protein has also been shown to preferentially
associate with lipid rafts at these sites [18,19]. Lipid rafts
are enriched in sphingolipids and cholesterol and are the
site of localization for the γ-secretase complex [17], which
is the enzyme responsible for the intramembranous cleav-
age of APP leading to the production of Aβ40 and Aβ42,
among others [20]). Since α-synuclein localizes to the
exact microdomain where APP processing takes place
[17], it is a distinct possibility that the two proteins inter-
act. Furthermore, research has suggested that α-synuclein
expression is up-regulated in AD cases [21]. Overall these
papers suggest that α-synuclein may be the primary insult
leading to aggregation of the protein and subsequent neu-
rodegeneration. While there exist several contradictory
reports as to whether α-synuclein associates with Aβ con-
taining plaques [9] it is likely that α-synuclein plays a con-
tributing role in AD, PD and other diseases.
Over the years several publications have called into ques-
tion the direct correlation between plaque and Lewy body
pathology in AD and PD and the respective neuronal loss
[22]). In addition, numerous papers recently suggested
that a small increase in α-synuclein expression is the cel-
lular response to oxidative stresses and confers a higher
viability to the cells [23,24]. This sheds light on a differ-
ent, neuroprotective property of α-synuclein in which the
α-synuclein indeed is called upon in the times of cellular
Sandwich ELISA of 6-month-old APP and APP/Snca-/- animals Figure 1
Sandwich ELISA of 6-month-old APP and APP/Snca-/- animals. 
Absence of α-synuclein did not lead to significant alterations 
in the levels total Aβ40 and Aβ42.
Immunostaining of 9- and 12-month-old APP and APP/Snca-/-  brains Figure 2
Immunostaining of 9- and 12-month-old APP and APP/Snca-/- 
brains. A. Sections were stained with 6E10 antibody to 
detect the total number of amyloid beta plaques. Scale bar 
denotes 100 μm. B. Representation of the number of plaques 
per section per hemisphere. While the variability was much 
higher in the APP/Snca-/- animals, there was no significant dif-
ference in the average number of plaques. N = 3 every 4th 
section was examined. C. Western Blots of 12-month-old 
APP and APP/Snca-/- brain homogenates. The protein was 
separated using 10% SDS-PAGE, transferred to a nitrocellu-
lose membrane, and probed with antibodies against β-synu-
clein, synaptophysin and α-tubulin. No differences in protein 
expression could be detected.Molecular Neurodegeneration 2007, 2:6 http://www.molecularneurodegeneration.com/content/2/1/6
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distress to help clear the insult [25]. In fact, our data that
the amyloid plaques are increased in the absence of α-
synuclein at old age suggests that α-synuclein may indeed
serve as a chaperone helping the cells to clear protein
deposits. While we were unable to detect any effect on the
onset of plaque deposition in the APP animals, the dis-
tinct effect that α-synuclein has at a later stage of the
pathology (18 months) is striking. Hence, α-synuclein
does not appear to be involved in the onset of plaque dep-
osition, but it is clearly involved in prevention of further
accumulation in later stages of the pathology, maybe in
clearing the Aβ fragments, possibly from the site of gener-
ation, to prevent further pathological development.
Although many studies have suggested that α-synuclein is
the culprit leading to neuronal cell death, it seems equally
likely that under physiological conditions the protein
presents a deterrent to the accumulation of other proteins
whose accumulation might be more toxic to the cell. To
date, α-synuclein has been shown to interact with a vari-
ety of proteins and is involved in a variety of diseases such
as Parkinson's disease, AD, as well as Sandhoff disease
[26], and it appears that the protein might play a more
basic role in cellular defense from diseases. The role of the
soluble protein might be to identify toxic proteins and
Plaque analysis of 18-month-old APP and APP/Snca-/- animals Figure 3
Plaque analysis of 18-month-old APP and APP/Snca-/- animals. 
A. Sections were stained with 6E10 antibody or thioflavine S 
as indicated. 6E10 staining revealed the total plaque load 
while thioflavine S detected mature plaques only. The plaque 
density is much higher in mice lacking α-synuclein when com-
pared to APP controls. Scale bar: 100 μm. B. Bar graph indi-
cating the density of plaques per square area. The plaque 
density in the APP/Snca-/- animals exceeds that of the APP 
animals by 3–4 fold. N = 4, ***p < 0.001
Western blotting of 18-month-old of APP and APP/Snca-/-  animals Figure 4
Western blotting of 18-month-old of APP and APP/Snca-/- 
animals. A. 10 μg of forebrain lysates were separated on 
SDS-PAGE, transferred to a nitrocellulose membrane and 
probed with antibodies against α-synuclein, APP, synapto-
physin and α-tubulin. No difference in APP or β-synuclein 
expression could be detected. α-synuclein was absent from 
APP/Snca-/- animals, and synaptophysin levels were increase in 
APP/Snca-/- animals. B. Quantification of band intensity of syn-
aptophysin from APP vs APP/Snca-/- animals. Data was nor-
malized to tubulin bands (**p < 0.01).Molecular Neurodegeneration 2007, 2:6 http://www.molecularneurodegeneration.com/content/2/1/6
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bind to them to induce a cellular defense mechanism. In
this scenario, under pathological conditions the amount
of α-synuclein-containing aggregates is simply too much
for the cellular machinery to handle, leading to intracellu-
lar aggregates as in the case of PD and Sandhoff disease or
extracellular aggregates as in the case of AD. While many
studies over the past year have indicated that α-synuclein
has a protective role in neurons in vitro, to our knowledge
this is the first report investigating the effect that the
absence of α-synuclein has on the disease progression
under pathological circumstances. There is no doubt that
the aggregation of an otherwise neuroprotective protein
could lead to pathological conditions if its natural
response leads to protein aggregation and up-regulation
of stress induced pathways. It is possible that the fact that
α-synuclein was first identified as the protein whose over-
expression leads to Parkinson's disease has masked its true
role as a neuroprotector.
Conclusion
Our study investigates the effect of the absence of α-synu-
clein in the progression of a pathological hallmark of AD.
In this study we identified α-synuclein as a protein influ-
encing the progression of plaque deposition in a trans-
genic mouse model of AD. Our data support a protective
role of α-synuclein against amyloid pathology at a later
stage, and offer an alternative explanation to the aggrega-
tion of α-synuclein under pathological conditions.
Methods
Mice
The Tg2576 APP transgenic mice and α-synuclein knock-
out mice have been described, and they were on B6SJL F1
and C57BL/6J backgrounds, respectively [14,17]. These
mice were crossed to generate APP transgenic on α-synu-
clein heterozygous background, which were then crossed
with  α-synuclein heterozygous mice to produce APP
transgenic mice on either wild-type or homozygous null
for α-synuclein. The resulting animals were 87.5% C57
and 12.5% SJL. Animals were age- and sex-matched with
a minimum N = 3 per study. All animal experiments were
performed in accordance with the Baylor College of Med-
icine Institutional Animal Care and Use Committee and
with national regulations and policies.
Antibodies
The following antibodies were used in this study: to detect
plaques and Aβ fragments 6E10 antibody (Signet, mouse
monoclonal) was used. Synaptophysin (Dako Cytoma-
tion, rabbit polyclonal) antibody was used as a marker for
pre-synaptic terminals, α-synuclein (BD Transduction
Laboratories, mouse monoclonal) antibody was used to
localize the protein of interest and ensure its absence in
knockout animals, β-synuclein (Chemicon, rabbit poly-
clonal) and MAP2 (Sigma, mouse monoclonal) antibod-
ies were used to locate post-synaptic termini; to ensure
equal loading we used α-tubulin (mouse) antibody.
Immunohistochemistry
All animals were anesthetized with avertin prior to per-
fusion and fixation in 4% PFA. Tissues were dehydrated
using an ethanol gradient and subsequently paraffin
embedded. Tissues were sectioned at a thickness of 6 μm.
Wax was melted at 65°C and sections were deparaffinized
in xylenes and re-hydrated via an ethanol gradient. Anti-
gen retrieval was performed using citric acid treatment
(1.8 mM citric acid, 8.2 mM sodium citrate) for 10 min-
utes boiling, and cooled at room temperature for 30 min-
utes thereafter. Sections were blocked with 10% Goat
Serum and incubated with primary antibody overnight at
4°C. Secondary antibody incubation was performed at
room temperature for one hour. To visualize plaques,
6E10 staining was developed using a horseradish peroxi-
dase system (DAB, Vectastain); secondary antibodies for
other stains were conjugated to a fluorophore. Images
were taken using a Zeiss microscope and Axioskop soft-
ware.
Thioflavine S staining
Paraffin embedded sections were deparaffinized and rehy-
drated. Subsequently the sections were incubated in
0.01% thioflavine S in PBS for 10 minutes, decolorized
with 2 washes of 95% ethanol and re-hydrated with PBS.
Plaques were visualized using Axioskop (Zeiss) and Axio-
vision software. Plaque counts were performed manually
(9 and 12 month old animals) or using Image J software
(18 month old animals).
Western Blotting
Brains were homogenized using NP40 lysis buffer (50
mM Tris pH 7.4, 150 mM NaCl, 10% Glycerol, 1% NP40)
containing Complete Protease Inhibitor Cocktail (Roche).
After 3 times 10 pulses of sonication the homogenates
were spun at 14000 rpm for 1 hour. Protein concentra-
tions were determined using Bio-Rad Dc Protein Assay
(Bio-Rad). Equal amounts of protein were loaded on a
10% SDS-PAGE run at 100 V for 1.5 hours at room tem-
perature and transferred onto a nitrocellulose membrane.
Membranes were blocked one hour using 5% non-fat dry
milk in PBS containing 0.1% Tween-20 (Sigma). Primary
antibody incubation was done in blocking solution over-
night at 4°C in constant agitation. Secondary antibody
application was performed at room temperature for 1
hour. Bands were visualized using Immobilon™ Western
ECL system (Millipore).
Sandwich ELISA
Sandwich ELISAs for quantifying human Aβ40 and Aβ42
were performed as described using 6E10 as the capture
antibody and AB112 and AB115 as detection antibodiesMolecular Neurodegeneration 2007, 2:6 http://www.molecularneurodegeneration.com/content/2/1/6
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which recognize Aβ40 and Aβ42 specifically [27]. Briefly,
four volumes of TBS buffer (v/w) were used to homoge-
nize brain samples, which were centrifuged at 8000 g for
1 hour. The pellet was resuspended in 5 M guanidine (2
volumes) and sonicated. 20 μl of homogenate was diluted
with 10 volumes of loading buffer. After centrifugation at
8000 g for 30 minutes, the samples were loaded into wells
for Aβ peptide detection. 100 μl of 6E10 (4 μg/ml) diluted
in carbonate-bicarbonate buffer, pH 9.6, were added to
coated microtiter plates and incubated at 4°C overnight.
After washing plates with PBS containing 0.05% of
Tween-20 (PBST), plates were blocked for 1 hour with 200
μl of PBST with 1% BSA. After washing the plate, 100 μl of
standards was applied and incubated for 2 hours at room
temperature or 4°C overnight. After washing, plates were
incubated with biotinylated AB112 or AB115 diluted
1:1000 and 1:500, respectively, in PBST at room tempera-
ture for 1 hr 30 min. After washing, neutravidin-horserad-
ish peroxidase (Pierce) diluted 1:5000 in PBST was added
and incubated for 1 hour at room temperature. After
washing the plate 3 times, 100 μl/ml of TMB solution was
added and incubated for 15–30 min at room temperature.
The color development was stopped by adding 100 μl/
well stop solution (1 M phosphoric acid). The optical den-
sity (OD) was measured at 490 nm by a microELISA
reader. The concentrations of Aβ40 and Aβ42 in the sam-
ples were calculated from the standard curve within the
linear range for each plate, respectively. Six forebrain sam-
ples/genotype/age were analyzed each in triplicate.
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